VisEn is developing an expanding range of fluorescence agents, with different mechanisms of action, to selectively highlight in vivo the biological targets, biomarkers and pathways that underlie disease progression and therapeutic response.
For in vivo imaging, agents must have high affinity and specificity for their intended target and overcome the numerous "biological hurdles" present in complex living organisms, such as rapid excretion, non-specific accumulation in non-target tissues, metabolism, clearance and pharmacologic delivery barriers. Even in animal models, biocompatibility and toxicity profiles are critical to enable a truly non-invasive assessment of biological activity and therapeutic response.
Equally important, is to develop the imaging agent with a mechanism of action best suited for the intended application and one which yields the greatest amount of information.
